Personalized medicine is an important and evolving research area for pancreatic cancer. By identifying patients’ own genetic and tumor make-up, as well as their specific mutations, physicians can create custom treatment strategies unique to each patient’s needs. Lustgarten-funded research is exploring various approaches and technologies for the most effective way to personalize medicine, including replicating 3D tumor cells in the lab to create organoids.
In this live-streaming discussion, we'll take you from the clinic to the lab to show you how personalized medicine may transform the future of pancreatic cancer treatment. Discussion will include organoid research at Cold Spring Harbor Laboratory (CSHL) and the current PASS-01 clinical trial.
David Tuveson, MD, PhD, Chief Scientist and Director of the Lustgarten Foundation Dedicated Pancreatic Cancer Research Lab at Cold Spring Harbor Laboratory (CSHL)
Dennis Plenker, PhD, Technical Manager, Lustgarten Foundation Dedicated Pancreatic Cancer Lab at CSHL
TBD, Northwell Health Physician
Moderated by Andrew Rakeman, PhD, VP Research, Lustgarten Foundation